{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:22:29Z","timestamp":1762273349970},"reference-count":27,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,27]]},"DOI":"10.7759\/cureus.67941","type":"journal-article","created":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T15:18:43Z","timestamp":1724771923000},"source":"Crossref","is-referenced-by-count":2,"title":["A Randomized Controlled Trial Comparing the Effects of Vilazodone, Escitalopram, and Vortioxetine Monotherapy on the Metabolic Parameters in Patients With Major Depressive Disorder"],"prefix":"10.7759","author":[{"given":"N Simple","family":"Santi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sashi B","family":"Biswal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birendra Narayan","family":"Naik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyoti Prakash","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhabagrahi","family":"Rath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/wps.21110","article-title":"Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management","volume":"22","author":"Berk M","year":"2023","unstructured":"Berk M, K\u00f6hler-Forsberg O, Turner M, et al.. Comorbidity between major depressive disorder and physical diseases: a comprehensive review of epidemiology, mechanisms and management. World Psychiatry. 2023, 22:366-87. 10.1002\/wps.21110","journal-title":"World Psychiatry"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3390\/ijtm4010010","article-title":"Advancements exploring major depressive disorder: insights on oxidative stress, serotonin metabolism, BDNF, HPA axis dysfunction, and pharmacotherapy advances","volume":"5","author":"Correia AS","year":"2024","unstructured":"Correia AS, Vale N. Advancements exploring major depressive disorder: insights on oxidative stress, serotonin metabolism, BDNF, HPA axis dysfunction, and pharmacotherapy advances. Int J Transl Med. 2024, 5:176-96. 10.3390\/ijtm4010010","journal-title":"Int J Transl Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15630","article-title":"Depression and type 2 diabetes: a causal relationship and mechanistic pathway","volume":"26","author":"Khawagi WY","year":"2024","unstructured":"Khawagi WY, Al-Kuraishy HM, Hussein NR, et al.. Depression and type 2 diabetes: a causal relationship and mechanistic pathway. Diabetes Obes Metab. 2024, 26:3031-44. 10.1111\/dom.15630","journal-title":"Diabetes Obes Metab"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1017\/neu.2019.17","article-title":"Inflammation, insulin resistance and neuroprogression in depression","volume":"32","author":"Leonard BE","year":"2020","unstructured":"Leonard BE, Wegener G. Inflammation, insulin resistance and neuroprogression in depression. Acta Neuropsychiatr. 2020, 32:1-9. 10.1017\/neu.2019.17","journal-title":"Acta Neuropsychiatr"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2019.01.016","article-title":"Brain insulin resistance: a treatment target for cognitive impairment and anhedonia in depression","volume":"315","author":"Hamer JA","year":"2019","unstructured":"Hamer JA, Testani D, Mansur RB, Lee Y, Subramaniapillai M, McIntyre RS. Brain insulin resistance: a treatment target for cognitive impairment and anhedonia in depression. Exp Neurol. 2019, 315:1-8. 10.1016\/j.expneurol.2019.01.016","journal-title":"Exp Neurol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104927","article-title":"The link between cognition and somatic conditions related to insulin resistance in the UK Biobank study cohort: a systematic review","volume":"143","author":"Fanelli G","year":"2022","unstructured":"Fanelli G, Mota NR, Salas-Salvad\u00f3 J, et al.. The link between cognition and somatic conditions related to insulin resistance in the UK Biobank study cohort: a systematic review. Neurosci Biobehav Rev. 2022, 143:104927. 10.1016\/j.neubiorev.2022.104927","journal-title":"Neurosci Biobehav Rev"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0200-2","article-title":"Comorbid depression in medical diseases","volume":"6","author":"Gold SM","year":"2020","unstructured":"Gold SM, K\u00f6hler-Forsberg O, Moss-Morris R, et al.. Comorbid depression in medical diseases. Nat Rev Dis Primers. 2020, 6:69. 10.1038\/s41572-020-0200-2","journal-title":"Nat Rev Dis Primers"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61611-6","article-title":"Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010","volume":"9","author":"Whiteford HA","year":"2013","unstructured":"Whiteford HA, Degenhardt L, Rehm J, et al.. Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. Lancet. 2013, 9:1575-86. 10.1016\/S0140-6736(13)61611-6","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2021.102111","article-title":"More treatment but no less depression: the treatment-prevalence paradox","volume":"91","author":"Ormel J","year":"2022","unstructured":"Ormel J, Hollon SD, Kessler RC, Cuijpers P, Monroe SM. More treatment but no less depression: the treatment-prevalence paradox. Clin Psychol Rev. 2022, 91:102111. 10.1016\/j.cpr.2021.102111","journal-title":"Clin Psychol Rev"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-021-00117-8","article-title":"The relationship between depression and risk of metabolic syndrome: a meta-analysis of observational studies","volume":"7","author":"Moradi Y","year":"2021","unstructured":"Moradi Y, Albatineh AN, Mahmoodi H, Gheshlagh RG. The relationship between depression and risk of metabolic syndrome: a meta-analysis of observational studies. Clin Diabetes Endocrinol. 2021, 7:4. 10.1186\/s40842-021-00117-8","journal-title":"Clin Diabetes Endocrinol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59074","article-title":"A randomized controlled trial comparing efficacy and safety of antidepressant monotherapy","volume":"16","author":"Santi NS","year":"2024","unstructured":"Santi NS, Biswal SB, Naik BN, Sahoo JP, Rath B. A randomized controlled trial comparing efficacy and safety of antidepressant monotherapy. Cureus. 2024, 16:e59074. 10.7759\/cureus.59074","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.62418","article-title":"A randomized controlled trial comparing the quality of life and medication adherence in patients on antidepressant monotherapy","volume":"16","author":"Santi NS","year":"2024","unstructured":"Santi NS, Biswal SB, Naik BN, Sahoo JP, Rath B. A randomized controlled trial comparing the quality of life and medication adherence in patients on antidepressant monotherapy. Cureus. 2024, 16:e62418. 10.7759\/cureus.62418","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.5152\/npa.2016.12373","article-title":"Metabolic effects of antidepressant treatment","volume":"54","author":"Olguner Eker \u00d6","year":"2017","unstructured":"Olguner Eker \u00d6, \u00d6zsoy S, Eker B, Do\u011fan H. Metabolic effects of antidepressant treatment. Noro Psikiyatr Ars. 2017, 54:49-56. 10.5152\/npa.2016.12373","journal-title":"Noro Psikiyatr Ars"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.37858","article-title":"An interim analysis of a randomized, open-label study of vilazodone, escitalopram, or vortioxetine for major depressive disorder","volume":"15","author":"Santi NS","year":"2023","unstructured":"Santi NS, Biswal SB, Naik BN, Sahoo JP, Rath B. An interim analysis of a randomized, open-label study of vilazodone, escitalopram, or vortioxetine for major depressive disorder. Cureus. 2023, 15:e37858. 10.7759\/cureus.37858","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.39997","article-title":"Quality of life and medication adherence in patients with major depressive disorder: an interim analysis of a randomized study","volume":"15","author":"Santi NS","year":"2023","unstructured":"Santi NS, Biswal SB, Naik BN, Sahoo JP, Rath B. Quality of life and medication adherence in patients with major depressive disorder: an interim analysis of a randomized study. Cureus. 2023, 15:e39997. 10.7759\/cureus.39997","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.42585","article-title":"Metabolic effects of antidepressants: results of a randomized Study\u2019s interim analysis","volume":"15","author":"Santi NS","year":"2023","unstructured":"Santi NS, Biswal SB, Naik BN, Sahoo JP, Rath B. Metabolic effects of antidepressants: results of a randomized Study\u2019s interim analysis. Cureus. 2023, 15:e42585. 10.7759\/cureus.42585","journal-title":"Cureus"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.45098","article-title":"Comparison of Hamilton Depression Rating Scale and Montgomery-\u00c5sberg Depression Rating Scale: baked straight from a randomized study","volume":"15","author":"Santi NS","year":"2023","unstructured":"Santi NS, Biswal SB, Naik BN, Sahoo JP, Rath B. Comparison of Hamilton Depression Rating Scale and Montgomery-\u00c5sberg Depression Rating Scale: baked straight from a randomized study. Cureus. 2023, 15:e45098. 10.7759\/cureus.45098","journal-title":"Cureus"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton M","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960, 23:56-62. 10.1136\/jnnp.23.1.56","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref19","unstructured":"R. A language and environment for statistical computing, Vienna, Austria. (2020). Accessed: July 31, 2024: https:\/\/www.r-project.org\/."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.10.56","article-title":"Vortioxetine versus sertraline in metabolic control, distress and depression in Mexican patients with type 2 diabetes","volume":"7","author":"Tovilla-Z\u00e1rate CA","year":"2019","unstructured":"Tovilla-Z\u00e1rate CA, P\u00e9rez-Mandujano A, Ram\u00edrez-Gonz\u00e1lez IR, et al.. Vortioxetine versus sertraline in metabolic control, distress and depression in Mexican patients with type 2 diabetes. Ann Transl Med. 2019, 7:656. 10.21037\/atm.2019.10.56","journal-title":"Ann Transl Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14497","article-title":"Neurological and metabolic related pathophysiologies and treatment of comorbid diabetes with depression","volume":"30","author":"Li S","year":"2024","unstructured":"Li S, Yang D, Zhou X, et al.. Neurological and metabolic related pathophysiologies and treatment of comorbid diabetes with depression. CNS Neurosci Ther. 2024, 30:e14497. 10.1111\/cns.14497","journal-title":"CNS Neurosci Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/da.22387","article-title":"Type 2 diabetes in patients with major depressive disorder: a meta\u2010analysis of prevalence estimates and predictors","volume":"32","author":"Vancampfort D","year":"2015","unstructured":"Vancampfort D, Mitchell AJ, De Hert M, Sienaert P, Probst M, Buys R, Stubbs B. Type 2 diabetes in patients with major depressive disorder: a meta\u2010analysis of prevalence estimates and predictors. Depress Anxiety. 2015, 32:763-73. 10.1002\/da.22387","journal-title":"Depress Anxiety"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2019.00788","article-title":"Brain insulin resistance and hippocampal plasticity: mechanisms and biomarkers of cognitive decline","volume":"13","author":"Spinelli M","year":"2019","unstructured":"Spinelli M, Fusco S, Grassi C. Brain insulin resistance and hippocampal plasticity: mechanisms and biomarkers of cognitive decline. Front Neurosci. 2019, 13:788. 10.3389\/fnins.2019.00788","journal-title":"Front Neurosci"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.899069","article-title":"The serotonergic system dysfunction in diabetes mellitus","volume":"16","author":"Cai Y","year":"2022","unstructured":"Cai Y, Li X, Zhou H, Zhou J. The serotonergic system dysfunction in diabetes mellitus. Front Cell Neurosci. 2022, 16:899069. 10.3389\/fncel.2022.899069","journal-title":"Front Cell Neurosci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2022.05.098","article-title":"Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness","volume":"311","author":"Baldwin DS","year":"2022","unstructured":"Baldwin DS, Necking O, Schmidt SN, Ren H, Reines EH. Efficacy and safety of vortioxetine in treatment of patients with major depressive disorder and common co-morbid physical illness. J Affect Disord. 2022, 311:588-94. 10.1016\/j.jad.2022.05.098","journal-title":"J Affect Disord"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2022.104731","article-title":"Antidepressants for depressed patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of short-term randomized controlled trials","volume":"139","author":"Srisurapanont M","year":"2022","unstructured":"Srisurapanont M, Suttajit S, Kosachunhanun N, Likhitsathian S, Suradom C, Maneeton B. Antidepressants for depressed patients with type 2 diabetes mellitus: a systematic review and network meta-analysis of short-term randomized controlled trials. Neurosci Biobehav Rev. 2022, 139:104731. 10.1016\/j.neubiorev.2022.104731","journal-title":"Neurosci Biobehav Rev"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s13098-023-01149-z","article-title":"Antidepressants and type 2 diabetes: highways to knowns and unknowns","volume":"15","author":"Alruwaili NS","year":"2023","unstructured":"Alruwaili NS, Al-Kuraishy HM, Al-Gareeb AI, et al.. Antidepressants and type 2 diabetes: highways to knowns and unknowns. Diabetol Metab Syndr. 2023, 15:179. 10.1186\/s13098-023-01149-z","journal-title":"Diabetol Metab Syndr"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/287392-a-randomized-controlled-trial-comparing-the-effects-of-vilazodone-escitalopram-and-vortioxetine-monotherapy-on-the-metabolic-parameters-in-patients-with-major-depressive-disorder","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T15:18:48Z","timestamp":1724771928000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/287392-a-randomized-controlled-trial-comparing-the-effects-of-vilazodone-escitalopram-and-vortioxetine-monotherapy-on-the-metabolic-parameters-in-patients-with-major-depressive-disorder"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,27]]},"references-count":27,"URL":"https:\/\/doi.org\/10.7759\/cureus.67941","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,27]]}}}